{"denoms":[{"counts":[{"groupId":"BG000","value":"163"}],"units":"Participants"}],"groups":[{"description":"bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for 4 cycles","id":"BG000","title":"All Study Participants"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.04","value":"63.7"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"77"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"86"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}]}],"title":"France"},{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}]}],"title":"Germany"},{"categories":[{"measurements":[{"groupId":"BG000","value":"23"}]}],"title":"Greece"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Hungary"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"Lithuania"},{"categories":[{"measurements":[{"groupId":"BG000","value":"19"}]}],"title":"Poland"},{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}]}],"title":"Serbia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}]}],"title":"Spain"},{"categories":[{"measurements":[{"groupId":"BG000","value":"19"}]}],"title":"Turkey"},{"categories":[{"measurements":[{"groupId":"BG000","value":"21"}]}],"title":"United Kingdom"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"modified Intent to Treat Population consisting of all 163 participants with at least 1 dose and 1 post baseline efficacy assessment.: Complete and Partial Responders (non-randomized), n=144. Stable Disease (randomized to VD, VDC, and VDL), n=19."}